We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma.
- Authors
Gascoyne, Randy; Kendrick, Samantha; Schmelz, Monika; Rimsza, Lisa; Scott, David; Connors, Joseph; Sehn, Laurie; Slack, Graham; Farinha, Pedro; Tan, King; Persky, Daniel; Puvvada, Soham; Rimsza, Lisa M; Scott, David W; Slack, Graham W; Tan, King L; Connors, Joseph M; Gascoyne, Randy D
- Abstract
The article talks about survival of Diffuse large B-cell lymphoma (DLBCL) patients not surviving much after diagnosis due to relapse of disease. It talks of the negative phenotypic prognostic indicators like major histocompatibility class II (MHCII) surface protein being a strong predictor of poor patient survival rate. It also makes a mention of poor host tumor-infiltrating T-cell responsible for reducing immune surveillance.
- Subjects
DIFFUSE large B-cell lymphomas; DISEASE relapse; IMMUNE system; HISTOCOMPATIBILITY testing; SURVIVAL; DIAGNOSIS; ANTINEOPLASTIC agents; THERAPEUTIC use of monoclonal antibodies; B cell lymphoma; CYTOPLASM; HISTOCOMPATIBILITY antigens; PROGNOSIS
- Publication
Virchows Archiv: European Journal of Pathology, 2017, Vol 470, Issue 1, p113
- ISSN
0945-6317
- Publication type
journal article
- DOI
10.1007/s00428-016-2041-7